Glaukos (GKOS)

• Market cap: $6.92B
• 1 day: -20.01%
• 5 days: -14.35%
• 1 month: -21.00%
• 3 months: -10.62%
• 6 months: -3.17%
• Year to date: -15.90%
• 1 year: 35.66%
• 5 years: 96.78%
• 10 years: 303.20%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.

Employees: 907

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

30% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 40

20% more capital invested

Capital invested by funds: $7.13B [Q3] → $8.55B (+$1.41B) [Q4]

9% more repeat investments, than reductions

Existing positions increased: 114 | Existing positions reduced: 105

0% more funds holding

Funds holding: 313 [Q3] → 314 (+1) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]

5.34% less ownership

Funds ownership: 108.69% [Q3] → 103.35% (-5.34%) [Q4]

29% less call options, than puts

Call options by funds: $46.1M | Put options by funds: $64.7M

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $120 5% downside
• Avg. target: $169 34% upside
• High target: $200 59% upside

10 analyst ratings

• positive: 9 90%
• neutral: 0 0%
• negative: 1 10%

Wells Fargo Larry Biegelsen 66% 1-year accuracy 31 / 47 met price target	27% upside $160	Overweight Maintained	21 Feb 2025
Needham David Saxon 37% 1-year accuracy 24 / 65 met price target	40% upside $176	Buy Maintained	21 Feb 2025
Mizuho Anthony Petrone 48% 1-year accuracy 14 / 29 met price target	59% upside $200	Outperform Upgraded	19 Feb 2025
Piper Sandler Matt O'Brien 64% 1-year accuracy 35 / 55 met price target	43% upside $180	Overweight Reiterated	27 Jan 2025
Stifel Thomas Stephan 44% 1-year accuracy 8 / 18 met price target	39% upside $175	Buy Maintained	31 Dec 2024